Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment NHS England has made of the effectiveness of the Translarna drug in treating the limb girdle 2b form of Duchenne muscular dystrophy.

NHS England has advised that limb girdle 2b is a form of muscular dystrophy distinct from Duchenne muscular dystrophy.

NHS England understands that Ataluren (Translarna) has not been trialed by the manufacturers of this drug, PTC Therapeutics, as a treatment for this disease and therefore no assessment has been made.